Arrhythmogenic Right Ventricular Cardiomyopathy: Difference between revisions

Jump to navigation Jump to search
m
no edit summary
mNo edit summary
Line 39: Line 39:
</ul>
</ul>
|}
|}
In 2009 three more criteria were added<cite>cox</cite>:
In 2009 these criteria were updated<cite>cox</cite>, see the table below.
*Terminal activation duration of QRS≥55ms
*ventricular tachycardia with left bundle branch block morphology and superior axis, and
*genetic criteria.


'''Treatment''' focuses on avoiding complications.<cite>ACC2006</cite>
'''Treatment''' focuses on avoiding complications.<cite>ACC2006</cite>
Line 58: Line 55:
</gallery>
</gallery>


==Table 1==
== Revised Task Force Criteria ARVD / ARVC==
{| class="wikitable"
{| class="wikitable"
|+ Table 1. Comparison of Original and Revised Task Force Criteria
|+ Comparison of Original and Revised Task Force Criteria
! style="width:500px" | Original Task Force Criteria
! style="width:500px" | Original Task Force Criteria
! style="width:500px" | Revised Task Force Criteria
! style="width:500px" | Revised Task Force Criteria
|-
|-
| colspan="2" | I. Global or regional dysfunction and structural alterations<sup>&lowast;</sup>
| colspan="2" | '''I. Global or regional dysfunction and structural alterations<sup>&lowast;</sup>'''
|-
|-
| colspan="2" style="padding-left:12px" | Major
| colspan="2" style="padding-left:12px" | '''Major'''
|-
|-
| valign="top" style="padding-left:24px" |
| valign="top" style="padding-left:24px" |
Line 87: Line 84:
* Regional RV akinesia, dyskinesia, or aneurysm
* Regional RV akinesia, dyskinesia, or aneurysm
|-
|-
| colspan="2" style="padding-left:12px"  | Minor
| colspan="2" style="padding-left:12px"  | '''Minor'''
|-
|-
| valign="top" style="padding-left:24px"  |
| valign="top" style="padding-left:24px"  |
Line 106: Line 103:
** <em>or</em> RV ejection fraction &gt;40% to &le;45%
** <em>or</em> RV ejection fraction &gt;40% to &le;45%
|-
|-
| colspan="2" | II. Tissue characterization of wall
| colspan="2" | '''II. Tissue characterization of wall'''
|-
|-
| colspan="2" style="padding-left:12px" | Major
| colspan="2" style="padding-left:12px" | '''Major'''
|-
|-
| valign="top" style="padding-left:24px" |
| valign="top" style="padding-left:24px" |
Line 121: Line 118:
* Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with fibrous replacement of the RV free wall myocardium in &ge;1 sample, with or without fatty replacement of tissue on endomyocardial biopsy
* Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with fibrous replacement of the RV free wall myocardium in &ge;1 sample, with or without fatty replacement of tissue on endomyocardial biopsy
|-
|-
| colspan="2" | III. Repolarization abnormalities
| colspan="2" | '''III. Repolarization abnormalities'''
|-
|-
| colspan="2" style="padding-left:12px" | Major
| colspan="2" style="padding-left:12px" | '''Major'''
|-
|-
| &nbsp;
| &nbsp;
Line 157: Line 154:
* Terminal activation duration of QRS &ge;55 ms measured from the nadir of the S wave to the end of the QRS, including R&acute;, in V<sub>1</sub>, V<sub>2</sub>, or V<sub>3</sub>, in the absence of complete right bundle-branch block
* Terminal activation duration of QRS &ge;55 ms measured from the nadir of the S wave to the end of the QRS, including R&acute;, in V<sub>1</sub>, V<sub>2</sub>, or V<sub>3</sub>, in the absence of complete right bundle-branch block
|-
|-
| colspan="2" | V. Arrhythmias
| colspan="2" | '''V. Arrhythmias'''
|-
|-
| colspan="2" style="padding-left:12px" | Major
| colspan="2" style="padding-left:12px" | '''Major'''
|-
|-
|
|
Line 174: Line 171:
* &gt;500 ventricular extrasystoles per 24 hours (Holter)
* &gt;500 ventricular extrasystoles per 24 hours (Holter)
|-
|-
| colspan="2" | VI. Family history
| colspan="2" | '''VI. Family history'''
|-
|-
| colspan="2" style="padding-left:12px" | Major
| colspan="2" style="padding-left:12px" | '''Major'''
|-
|-
| style="padding-left:24px" valign="top" |
| style="padding-left:24px" valign="top" |

Navigation menu